<DOC>
	<DOCNO>NCT00522730</DOCNO>
	<brief_summary>The purpose study determine tolerance lipid metabolism safety short-term parenteral nutrition compare enteral nutrition critically ill patient liver failure .</brief_summary>
	<brief_title>Safety Tolerance Lipids Parenteral Enteral Nutrition Critically Ill Patients With Liver Failure</brief_title>
	<detailed_description>An impaired lipid metabolism often find patient liver disease assume influence prognosis . The central role lipid metabolism pathophysiology fatty liver disease steatohepatitis well establish . In cirrhotic patient , serum lipid level mostly decrease related severity liver failure ; addition , structure composition lipoproteins differ healthy individual . A reduction high-density lipoprotein associate high cytokine level poorer clinical outcome septic patient . Furthermore , oxidative stress induce septic complication critically ill patient liver failure may lead hepatocellular injury activation systemic inflammation cascade . In set , influence nutrition lipid metabolism may impact severity liver failure associate complication . Although plasma clearance oxidation lipid consider normal majority patient cirrhosis , previous study report effect oral ingestion parenteral infusion lipid hour . The present randomized control trial conduct subgroup patient enrol SELLIFA-01 prospective study ( NCT00488917 ) . The purpose nutritional trial determine tolerance lipid metabolism safety isocaloric short-term parenteral nutrition compare enteral nutrition critically ill septic non septic patient liver failure . The nutrition deliver continuously 5 day provide daily energy supply correspond current rest energy expenditure determine indirect calorimetry , 35 % total energy requirement lipid , 15 % protein ( maximum 1.2g/kg ideal body weight/day ) , 50 % dextrose . A tight glucose control strategy implement avoid hyperglycemia . The trial design randomly assign 15 patient interventional group order detect 25 % increase plasma triglyceride level 80 % statistical power two-tailed type I error 5 % .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<criteria>All consecutive patient diagnosis chronic liver failure ; Planned total nutritional support ; Adult patient age 18 year , less 85 ; Admission ICU expect period &gt; 24 hour ; Informed consent patient nearest relative . Absolute contraindication enteral nutrition : total mechanical ileus , persistent vomiting , high output fistula , uncertain gastrointestinal anastomosis ; Absolute contraindication parenteral nutrition : severe hypertriglyceridemia &gt; 6 mmol/l ( &gt; 545 mg/dL ) , severe diabetic ketoacidosis ; Age le 18 year 85 ; Pregnancy , include HELLP syndrome ; Active malignancy metastasis ( localize hepatocellular carcinoma exclusion criterion ) ; Systemic chemotherapy last 4 week ( transarterial chemoembolisation localize hepatocellular carcinoma exclusion criterion ) ; Acquired immunodeficiency syndrome antiretroviral therapy ; Refusal patient nearest relative .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Liver failure</keyword>
	<keyword>Liver cirrhosis</keyword>
	<keyword>Parenteral nutrition</keyword>
	<keyword>Enteral nutrition</keyword>
	<keyword>Lipids</keyword>
	<keyword>Safety</keyword>
	<keyword>Drug tolerance</keyword>
</DOC>